A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma
OBJECTIVES: I. Determine the maximum tolerated dose of ganciclovir administered IV every 12
hours for 7 days in combination with adenovirus RSV-TK administered by direct intralesional
injection in patients with cutaneous or subcutaneous metastatic malignant melanoma. II.
Determine the dose limiting toxicities of this regimen in this patient population. III.
Evaluate the response (both local and at distant metastatic sites), duration of response,
response by ganciclovir dose, and any impact local treatment with adenovirus RSV-TK and
ganciclovir "suicide" gene therapy may have on overall survival in these patients.
OUTLINE: This is a dose escalation study of ganciclovir. Patients are stratified according
to response of the index lesion and other metastatic disease sites. Patients receive an
intratumoral injection of adenovirus RSV-TK on day 1. Ganciclovir IV is administered every
12 hours on days 3-10 for a total of 14 doses. Patients sustaining a partial response (PR)
or complete response (CR) may be retreated 2 weeks after documented PR or CR. Cohorts of 3-6
patients receive escalating doses of ganciclovir until the maximum tolerated dose (MTD) is
determined. The MTD is defined as the dose preceding that at which 2 of 6 patients
experience dose limiting toxicities. Patients are followed at 3 weeks, 4 weeks, 60 days,
then every 2 months for 6 months, and then every 3 months for 1.5 years.
PROJECTED ACCRUAL: A maximum of 27 patients will be accrued for this study.
Primary Purpose: Treatment
John C. Morris, MD
NCI - Metabolism Branch;MET
United States: Federal Government
|Baylor College of Medicine||Houston, Texas 77030|
|Clinical Genetherapy Branch||Bethesda, Maryland 20892|
|Metabolism Branch||Bethesda, Maryland 20892|